Fatal Pneumonia Associated with Temozolomide Therapy in Patients with Malignant Glioma
Fatal Pneumonia Associated with Temozolomide Therapy in Patients with Malignant Glioma
复制标题
恶性胶质瘤患者与替莫唑胺治疗相关的致命性肺炎
DOI:
10.1093/jjco/hys058
复制
发表时间:
2012
期刊:
影响因子:
2.4
通讯作者:
Gemma A
中科院分区:
文献类型:
--
作者:
Hayashi H;Saito Y;Kokuho N;Morimoto T;Kobayashi K;Tanaka T;Abe S;Fujita K;Azuma A;Gemma A
This report presents the cases of three patients with fatal pneumonia that was highly suspected to bePneumocystispneumonia (PCP) based on serological diagnosis. Their chest radiographs showed bilateral pneumonia and each had presented with severe respiratory failure requiring mechanical ventilation when they arrived at the hospital. Although bronchoscopical sampling could not be performed, their chest computed tomography imaging and a marked elevation of serum KL-6 and β-d-glucan levels were characteristic ofPneumocystispneumonia. All three were found to have been treated with temozolomide after surgery for malignant glioma. Temozolomide can causePneumocystispneumonia. The three patients did not receive prophylactic medication againstPneumocystispneumonia during treatment with temozolomide, and their histories suggested that all had delayed seeking treatment. It may be difficult to diagnosePneumocystispneumonia because the symptoms are not specific forPneumocystispneumonia and they tend to be similar to those of common respiratory infectious diseases. Therefore, patients who receive temozolomide therapy have the potential to develop fatal pneumonia and should be carefully observed. The patients should also be adequately informed aboutPneumocystispneumonia, and prophylaxis againstPneumocystispneumonia should be considered proactively before treatment with temozolomide is initiated.